Navigation Links
Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
Date:11/9/2010

MOUNTAIN VIEW, Calif., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2010 and provided a business update.  The net loss for the three and nine months ended September 30, 2010, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $0.6 million and $26.9 million, respectively, compared to a net loss of $12.4 million and $36.3 million in the comparable periods in 2009.  At September 30, 2010, Alexza had consolidated cash, cash equivalents and marketable securities of $52.7 million.

Alexza Business Updates

The following key events, listed in chronological order, occurred since the beginning of the third quarter of 2010:

  • Joseph L. Turner joined the Alexza Board of Directors and was elected to serve as Chair of the Board's Audit and Ethics Committee.
  • Alexza raised approximately $16.4 million in net proceeds in a registered direct offering through the sale of common stock and warrants, with the transaction closing in early August.
  • Darl Moreland joined Alexza as its Vice President, Quality.
  • Alexza licensed its Staccato® nicotine technology to Cypress Bioscience, Inc. (Cypress).  The Staccato nicotine technology is a novel electronic multi-dose delivery system designed to help people stop smoking, and is in pre-clinical development.
  • The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Company's New Drug Application (NDA) for AZ-004 (Staccato loxapine).  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  AZ-004 is being developed for the rapid treatment of agitation in
    '/>"/>

  • SOURCE Alexza Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
    2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
    3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
    4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
    5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
    6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
    7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
    8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
    9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
    10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
    11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
    (Date:10/22/2014)... ST. LOUIS , Oct. 21, 2014 /PRNewswire-USNewswire/ ... are often subtle or unnoticed, but new technology, ... patient outcomes and leading to earlier detection of ... now affects 29 million Americans. If left untreated, ... or even blindness. Recently, optometric ...
    (Date:10/22/2014)... , Oct. 22, 2014   Surefire Medical ... infusion systems designed to maximize targeted delivery of embolization ... to announce that oncologist John R. Daniels , ... Cancer Center, and surgical oncologist Steven C. Katz ... joined the Company,s Scientific Advisory Board (SAB).    ...
    Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
    ... Science, public health, and regulatory highlights for this ... in this document is designed for credentialed journalists. Release ... June 6, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... not contain any regulatory or enforcement actions due to ...
    ... – Regulus Therapeutics Inc ., a biopharmaceutical company ... microRNAs, today announced publication in the ... in mice on the antagonism of microRNA-33 (miR-33). The ... demonstrated that antagonism of miR-33 with ...
    Cached Medicine Technology:FDA News & Notes - Week of June 6, 2011 2Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 2Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 3Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 4Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 5Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 6
    (Date:10/22/2014)... 22, 2014 For Dr. Iris Hunter, a ... it’s an extension of her life’s mission. Her extensive experience ... the owner of FirstLight HomeCare, make it clear that Hunter’s ... me that my work makes a difference in the lives ... spirit, so after much research, I felt ready to start ...
    (Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
    (Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
    (Date:10/22/2014)... Viejo, CA (PRWEB) October 22, 2014 ... Jay Cormier, Sr. Vice President of Sales, will be ... the upcoming Meetings Technology Expo on October 28, at ... also be hosting a booth as well as a ... how Lintelus Meeting can create a more engaging event ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... only about half as likely as white women to become ... and the racial disparity persists even when donor eggs are ... patients became pregnant after IVF, compared to about 17 percent ... over two years to tease out the impact of race, ...
    Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
    ... A new multicenter study involving UCLA and the RAND ... is not an uncommon experience among fifth-grade students and ... mental health. , Study results show ... they perceived as discrimination and that the vast majority ...
    ... a Working Lunch into a Walking Lunch April 29 PITTSBURGH, ... 100 calories; and, to burn the calories in an average ... of a football field 33 times. Experts agree on the ... walking being one of the easiest and most inexpensive ways ...
    ... "Live Your Life Well(SM)" Offers 10 Proven Tools to ... From financial worries to family responsibilities, Americans are dealing ... these challenges, Mental Health America today launched an innovative ... deal with stressful times. Called Live Your Life ...
    ... worrisome rise in childhood obesity, Florida school districts have ... there is little research available to determine if the ... $2.2 million grant from the National Institutes of Health ... Florida State University College of Medicine researcher will explore ...
    ... April 27 The grassroots forum AmericaSpeakOn.org ... emerges as a pandemic level event," said former Health and Human ... a safe vaccine is ready." He goes on to say ... world to react aggressively." The full statement ...
    ... PRINCETON, N.J., April 27 NJHA,s Valerie Sellers was ... workshop on emergency preparedness in New York. The regional ... are part of an Institute of Medicine initiative to ... a public health emergency. The lessons are applicable to ...
    Cached Medicine News:Health News:Mental health problems more common in kids who feel racial discrimination 2Health News:Highmark Puts Employee Health First on National Walk@Lunch Day 2Health News:Highmark Puts Employee Health First on National Walk@Lunch Day 3Health News:New Campaign Helps Americans Deal With Stressful Times 2Health News:New Campaign Helps Americans Deal With Stressful Times 3Health News:FSU researcher wins $2.2 million grant to study childhood obesity 2Health News:FSU researcher wins $2.2 million grant to study childhood obesity 3Health News:AmericaSpeakOn.org Exclusive: Leavitt Asks 'How Prepared Is the US for the Swine Flu Pandemic?' 2Health News:NJHA's Sellers Serves on Institute of Medicine Preparedness Panel 2
    ... The PreView PHP is designed specifically for ... degeneration (AMD). ,This macular perimeter maps and ... progression of intermediate ("dry") AMD to the ... the brain's ability to compensate for small ...
    ... Pefakit APC-R FVL is a new ... 100% specificity for Activated Protein C Resistance ... (FV:Q506). In contrast to other commercially available ... from protein C or S, Lupus Anticoagulants, ...
    Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
    Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
    Medicine Products: